Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Vamlo

(Amlodipine Besilate Tablets)

 

COMPOSITION

Vamlo Tablets 10mg

Each tablet contains Amlodipine Besilate equivalent to Amlodipine 10 mg

Vamlo Tablets 5mg

Each tablet contains Amlodipine Besilate equivalent to Amlodipine 5 mg

 

PRODUCT DESCRIPTION

Vamlo Tablets 10 mg:

White to off white, flat, beveled edge, round uncoated tablets with a score-line on one side. Diameter 10.5mm

Vamlo Tablets 5 mg:

White to off white, flat, beveled edge, round uncoated tablets with a score-line on one side. Diameter 8.0mm

 

DESCRIPTION

VAMLO (Amlodipine Besilate) is a Calcium channel blocker. It is chemically designated (R. S.) 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate benzenesulphonate. Its empirical formula is C20H25CIN2O5C6H6O3S and its molecular weight is 567.1.

VAMLO

PHARMACOLOGY

Amlodipine is a calcium ion influx inhibitor (slow channel-blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into the cardiac and vascular smooth muscle.

 

The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on the vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined, but amlodipine reduces the total ischemic burden by the following 2 actions:

 

1) Amlodipine dilates the peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.

 

2) The mechanism of action of amlodipine probably involves dilation of the main coronary arteries and coronary arterioles, both in normal and ischemic regions.

 

This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal's or variant angina) and blunt smoking- induced coronary vasoconstriction. In patients with hypertension, once-daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24-hr interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration. In patients with angina, once-daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1 mm ST segment depression and decreases both angina attack frequency and nitroglycerine tablet consumption. Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes and gout.

 

Pharmacokinetics studies with cyclosporin have demonstrated that amlodipine does not significantly alter the pharmacokinetics of cyclosporin. Hemodynamic studies and a controlled clinical trial in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.

 

Pharmacokinetics

After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hrs post-dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution was approximately 21 L/kg. Absorption of amlodipine is unaffected by consumption of food. The terminal plasma elimination half-life is about 35-50 hrs and is consistent with once-daily dosing. Steady-state plasma levels are reached after 7-8 days of consecutive dosing. Amlodipine is extensively metabolized to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine. In vitro studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.

 

INDICATIONS

First-line treatment of hypertension and as the sole agent to control blood pressure in the majority of patients. Patients not adequately controlled on a single antihypertensive agent may benefit from the addition of Vamlo, which has been used successfully in combination with a thiazide diuretic, beta-adrenoceptor-blocking agent or an angiotensin-converting enzyme inhibitor. Vamlo is indicated for the 1st-line treatment of myocardial ischemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction / (Prinzmetal's or variant angina) of coronary vasculature. Vamlo may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. Vamlo may be used alone, as monotherapy or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or adequate doses of beta-blockers.

 

1    2

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer